ClinicalTrials.gg
CompletedNCT00824460PA21Updated Apr 1, 2014Results posted

Study of Phosphate Levels in Patients With Chronic Kidney Disease

A Phase 2 interventional study of 1.25 g PA21 (250 mg iron) and 5.0 g PA21 (1,000 mg iron) in Chronic Kidney Disease, sponsored by Vifor Pharma. Completed at 60 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-01.

Sponsored by Vifor Pharma (part of CSL Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing sevelamer in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Sevelamer · Renal Insufficiency, Chronic.

Enrollment
5th of 20
154 · median 67
Started
2008
with 1 other
Phase 2
6 of 20
none open now
Registered
9th of 20
by date

Among the 20 studies testing sevelamer in Renal Insufficiency, Chronic, this one is the 5th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 2, and was the 9th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

1 of the 20 studies testing sevelamer in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sevelamer

Sevelamer: first FDA approval 1998 (RENAGEL), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing sevelamer in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Hemodialysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • ≥ 18 years of age,
  • Receiving stable maintenance hemodialysis 3 times a week
  • On restricted phosphate diet at screening and throughout study
  • Receiving stable dose of phosphate binder for at least 1 month
  • Serum phosphate levels >1.78 mmol/L

Main Exclusion Criteria:

  • Uncontrolled hyperphosphatemia
  • Hypercalcemia at screening or during washout
  • Serum calcium \< 1.9 mmol/L (\<7.6 mg/dL)
  • Severe hyperparathyroidism (iPTH levels >600 ng/L)
  • Pregnancy or lactation
  • Iron deficiency anemia
  • History of hemochromatosis or ferritin >800 mg/L,
  • , or other significant concurrent liver disorders
  • Known positivity to
  • Use of oral iron preparations 1 month before screening,
  • Serious medical condition or uncontrolled systemic disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    1.25 g PA21

    Drug: 1.25 g PA21 (250 mg iron)

  • Experimental
    5.0 g PA21

    Drug: 5.0 g PA21 (1,000 mg iron)

  • Experimental
    7.5 g PA21

    Drug: 7.5 g PA21 (1,500 mg iron)

  • Experimental
    10.0 g PA21

    Drug: 10.0 g PA21 (2,000 mg iron)

  • Experimental
    12.5 g PA21

    Drug: 12.5 g PA21 (2,500 mg iron)

  • Experimental
    Sevelamer hydrochloride - active control

    Drug: Sevelamer hydrochloride

Interventions

  • Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.

  • Drug5.0 g PA21 (1,000 mg iron)

    Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).

  • Drug7.5 g PA21 (1,500 mg iron)

    Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).

  • Drug10.0 g PA21 (2,000 mg iron)

    Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).

  • Drug12.5 g PA21 (2,500 mg iron)

    Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).

  • Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Serum-phosphate Levels at the End of Treatment.

    Time frame: 6 weeks after baseline

Secondary outcomes

  1. Change From Baseline in Serum-phosphate Levels at Week 2

    Time frame: 2 weeks after baseline

  2. Change From Baseline in Serum-phosphate Levels at Week 4

    Time frame: 4 weeks after baseline

  3. Change From Baseline in Serum-phosphate Levels at Week 5

    Time frame: 5 weeks after baseline

07

Results

Posted Apr 1, 2014

Participant flow

Participant flow — Overall Study
Milestone1.25 g PA21 (250 mg Iron)5.0 g PA21 (1,000 mg Iron)7.5 g PA21 (1,500 mg Iron)10.0 g PA21 (2,000 mg Iron)12.5 g PA21 (2,500 mg Iron)Sevelamer Hydrochloride - Active Control
Started262625272426
Completed181720151518
Not completed8951298

Outcome measures

PrimaryChange From Baseline in Serum-phosphate Levels at the End of Treatment.
Time frame:
6 weeks after baseline
Reported as:
Mean · mmol/L
Change From Baseline in Serum-phosphate Levels at the End of Treatment.
mmol/L1.25 g PA21 (250 mg Iron)5.0 g PA21 (1,000 mg Iron)7.5 g PA21 (1,500 mg Iron)10.0 g PA21 (2,000 mg Iron)12.5g PA21 (2,500 mg Iron)Sevelamer Hydrochloride - Active Control
Change From Baseline in Serum-phosphate Levels at the End of Treatment.-0.042 ± 0.650-0.348 ± 0.684-0.404 ± 0.391-0.644 ± 0.551-0.547 ± 0.584-0.341 ± 0.436
SecondaryChange From Baseline in Serum-phosphate Levels at Week 2
Time frame:
2 weeks after baseline
Reported as:
Mean · mmol/L
Change From Baseline in Serum-phosphate Levels at Week 2
mmol/L1.25 g PA21 (250 mg Iron)5.0 g PA21 (1,000 mg Iron)7.5 g PA21 (1,500 mg Iron)10.0 g PA21 (2,000 mg Iron)12.5 g PA21 (2,500 mg Iron)Sevelamer Hydrochloride - Active Control
Change From Baseline in Serum-phosphate Levels at Week 2-0.03 ± 0.55-0.36 ± 0.35-0.41 ± 0.40-0.47 ± 0.62-0.46 ± 0.45-0.41 ± 0.44
SecondaryChange From Baseline in Serum-phosphate Levels at Week 4
Time frame:
4 weeks after baseline
Reported as:
Mean · mmol/L
Change From Baseline in Serum-phosphate Levels at Week 4
mmol/L1.25 g PA21 (250 mg Iron)5.0g PA21 (1,000 mg Iron)7.5 g PA21 (1,500 mg Iron)10.0 g PA21 (2,000 mg Iron)12.5g PA21 (2,500 mg Iron)Sevelamer Hydrochloride - Active Control
Change From Baseline in Serum-phosphate Levels at Week 4-0.03 ± 0.39-0.39 ± 0.45-0.32 ± 0.54-0.58 ± 0.53-0.53 ± 0.48-0.53 ± 0.35
SecondaryChange From Baseline in Serum-phosphate Levels at Week 5
Time frame:
5 weeks after baseline
Reported as:
Mean · mmol/L
Change From Baseline in Serum-phosphate Levels at Week 5
mmol/L1.25 g PA21 (250 mg Iron)5.0 g PA21 (1,000 mg Iron)7.5 g PA21 (1,500 mg Iron)10.0 g PA21 (2,000 mg Iron)12.5 g PA21 (2,500 mg Iron)Sevelamer Hydrochloride - Active Control
Change From Baseline in Serum-phosphate Levels at Week 5-0.05 ± 0.62-0.51 ± 0.62-0.40 ± 0.33-0.57 ± 0.55-0.58 ± 0.58-0.52 ± 0.37

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.25 g PA21 (250 mg Iron)—2/26 (7.7%)13/26 (50%)
5.0 g PA21 (1,000 mg Iron)—2/26 (7.7%)16/26 (61.5%)
7.5 g PA21 (1,500 mg Iron)—1/25 (4%)13/25 (52%)
10.0 g PA21 (2,000 mg Iron)—1/27 (3.7%)18/27 (66.7%)
12.5 g PA21 (2,500 mg Iron)—2/24 (8.3%)17/24 (70.8%)
Sevelamer Hydrochloride - Active Control—2/26 (7.7%)13/26 (50%)
Most frequent serious events
Most frequent serious events
Event1.25 g PA21 (250 mg Iron)5.0 g PA21 (1,000 mg Iron)7.5 g PA21 (1,500 mg Iron)10.0 g PA21 (2,000 mg Iron)12.5 g PA21 (2,500 mg Iron)Sevelamer Hydrochloride - Active Control
Staphylococcal sepsisInfections and infestations0/261/260/250/271/240/26
Fluid overloadMetabolism and nutrition disorders0/260/260/250/271/240/26
Ischaemic strokeNervous system disorders0/260/261/250/270/240/26
AsthmaRespiratory, thoracic and mediastinal disorders1/260/260/250/270/240/26
Diverticular perforationGastrointestinal disorders1/260/260/250/270/240/26
Myocardial infarctionCardiac disorders0/261/260/250/270/240/26
CholelithiasisHepatobiliary disorders0/260/260/250/270/241/26
Diabetic retinopathyEye disorders0/260/260/250/270/241/26
Rib fractureInjury, poisoning and procedural complications0/260/260/251/270/240/26
Most frequent other events
Showing 10 of 12
Most frequent other events
Event1.25 g PA21 (250 mg Iron)5.0 g PA21 (1,000 mg Iron)7.5 g PA21 (1,500 mg Iron)10.0 g PA21 (2,000 mg Iron)12.5 g PA21 (2,500 mg Iron)Sevelamer Hydrochloride - Active Control
HypophosphataemiaMetabolism and nutrition disorders2/264/262/258/277/242/26
HyperphosphataemiaMetabolism and nutrition disorders4/263/261/251/270/242/26
Faeces DiscoloureGastrointestinal disorders2/263/263/254/273/240/26
Muscle SpasmsMusculoskeletal and connective tissue disorders1/261/262/251/273/240/26
AnaemiaBlood and lymphatic system disorders0/260/263/250/270/240/26
HypotensionVascular disorders0/261/260/250/270/243/26
HypertensionVascular disorders1/260/262/250/272/241/26
NasopharyngitisInfections and infestations0/260/260/250/272/240/26
DiarrhoeaGastrointestinal disorders1/262/262/251/271/242/26
HypercalcaemiaMetabolism and nutrition disorders2/262/261/251/271/242/26

Baseline characteristics

For baseline characteristics data, from All Randomised patients was used.

Age, Categorical
Age, Categorical(Participants)1.25 g PA21 (250 mg Iron)5.0 g PA21 (1,000 mg Iron)7.5 g PA21 (1,500 mg Iron)10.0 g PA21 (2,000 mg Iron)12.5g PA21 (2,500 mg Iron)Sevelamer Hydrochloride - Active ControlTotal
<=18 years0000000
Between 18 and 65 years14181417141693
>=65 years1281110101061
Age, Continuous
Age, Continuous(years)1.25 g PA21 (250 mg Iron)5.0 g PA21 (1,000 mg Iron)7.5 g PA21 (1,500 mg Iron)10.0 g PA21 (2,000 mg Iron)12.5g PA21 (2,500 mg Iron)Sevelamer Hydrochloride - Active ControlTotal
Mean60.1 ± 12.2959.7 ± 13.8061.9 ± 13.7160.6 ± 12.7459.3 ± 12.3261.1 ± 11.0060.5 ± 12.50
Sex: Female, Male
Sex: Female, Male(Participants)1.25 g PA21 (250 mg Iron)5.0 g PA21 (1,000 mg Iron)7.5 g PA21 (1,500 mg Iron)10.0 g PA21 (2,000 mg Iron)12.5g PA21 (2,500 mg Iron)Sevelamer Hydrochloride - Active ControlTotal
Female97910111157
Male17191617131597
Region of Enrollment
Region of Enrollment(participants)1.25 g PA21 (250 mg Iron)5.0 g PA21 (1,000 mg Iron)7.5 g PA21 (1,500 mg Iron)10.0 g PA21 (2,000 mg Iron)12.5g PA21 (2,500 mg Iron)Sevelamer Hydrochloride - Active ControlTotal
United States44342421
Czech Republic0300328
Poland42320415
Romania24231012
Croatia53988740
Russian Federation75352628
Bulgaria33547123
Germany1000012
Switzerland0201115
08

Study locations

60 sites
  • Western Nephrology & Metabolic Disease
    Arvada, Colorado 80002, United States
  • Complete Renal Care
    Denver, Colorado 80220, United States
  • Pines Clinical Research
    Pembroke Pines, Florida 33028, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Nephrology Associates
    Fresh Meadows, New York 11365, United States
  • University Hospitals / Case Medical Center
    Cleveland, Ohio 44106, United States
  • Southeast Renal Research Institute
    Chattanooga, Tennessee 37404, United States
  • Nephrology Associates
    Nashville, Tennessee 37205, United States
  • Southwest Houston Research
    Houston, Texas 77099, United States
  • MHAT
    Gabrovo, 5300, Bulgaria
  • MHAT Plovdiv
    Plovdiv, 4003, Bulgaria
  • Department of Haemodialysis at MHAT
    Ruse, 7002, Bulgaria
  • 5th MHAT Sofia
    Sofia, 1233, Bulgaria
  • SHATCVD - National Cardiology Hospital
    Sofia, 1309, Bulgaria
  • MHAT "Tokuda Hospital Sofia"
    Sofia, 1407, Bulgaria
  • UMHAT "Alexandrovska" Dialysis Clinic
    Sofia, 1431, Bulgaria
  • UMHAT "Sveti Ivan Rilski"
    Sofia, 1431, Bulgaria
  • UMHAT "Sveta Anna"
    Sofia, 1784, Bulgaria
  • MDHAT Department of Haemodialysis and Nephrology
    Veliko Tarnovo, 5000, Bulgaria
  • Opca bonica Bjelovar
    Bjelovar, 43000, Croatia
  • Opca bolnica Karlovac
    Karlovac, 47000, Croatia
  • Opca bolnica
    Koprivnica, 48000, Croatia
  • Klinicka bolnica Osijek
    Osijek, 31000, Croatia
  • Klinicki bolnicki centar Rijeka
    Rijeka, 51000, Croatia
  • Klinicki bolnicki centar Split
    Split, 21000, Croatia
  • Opca bolnica Zadar
    Zadar, 23000, Croatia
  • Klinicka bolnica
    Zagreb, 10000, Croatia
  • Poliklinika Sveti Duh II
    Zagreb, 10000, Croatia
  • Klinicka bolnica Dubrava
    Zagreb, 10040, Croatia
  • Innef a.s. Hemodialyzancni stredisko
    Brno, 60200, Czech Republic
  • Nemocnice Nove Mesto na Morave
    Nove Město na Morave, 59231, Czech Republic
  • Nemocnice s poliklinikou v Novem Jicine
    Novy Jicin, 74101, Czech Republic
  • Klinika nefrologie VFN
    Prague, 2, Czech Republic
  • Nephrologische Gemeinschaftspraxis und Dialysezentrum
    Dortmund, 44263, Germany
  • Marienhospital
    Herne, 44625, Germany
  • Niepubliczny Zaklad Opieki Zdrowotnej
    Golub-Dobrzyń, 87-400, Poland
  • Katedra i Klinika Nefrologii
    Katowice, 40-027, Poland
  • NZOZ Dializa
    Olkusz, 32-300, Poland
  • Katedra i Klinika Nefrologii
    Poznań, 60-355, Poland
  • Samodzielny Specjalistyczny
    Siedlce, 26, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej
    Sieradz, 98-200, Poland
  • Centrum Dializy i Diagnostyki
    Warszawa, 01-809, Poland
  • Institutul Clinic Fundeni
    Bucuresti, 022328, Romania
  • Spitalul Universitar de Urgenta Bucuresti
    Bucuresti, 050098, Romania
  • Spitalul Clinic
    Lasi, 700503, Romania
  • SC Renamed Nefrodial SRL
    Oradea, 410562, Romania
  • S.C. Avitum S.R.L
    Targu Mures, 540136, Romania
  • GOU VPO Kazan
    Kazan, 420064, Russian Federation
  • GUZ City Clinical Hospital
    Moscow, 125284, Russian Federation
  • MUZ City Clinical Hospital
    Novosibirsk, 630120, Russian Federation
  • MLPU Clinical City Hospital
    Smolensk, 214001, Russian Federation
  • Saint-Petersburg CUS City Mariinskaya Hospital
    St. Petersburg, 191104, Russian Federation
  • Saint-Petersburg GUZ City Clinical Hospital
    St. Petersburg, 195257, Russian Federation
  • GOU VPO
    St. Petersburg, 195607, Russian Federation
  • Saint-Petersburg GUZ City Hospital
    St. Petersburg, 196247, Russian Federation
  • GOU VPO
    St. Petersburg, 197089, Russian Federation
  • CUS City Hospital
    St.Petersburg, 198205, Russian Federation
  • Kantonspital Aarau
    Aarau, 5001, Switzerland
  • Chuv Lausanne
    Lausanne, 1011, Switzerland
  • Universitatsspital Zurich
    Zürich, 8091, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Oct 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 4 years 6 months after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2009
First posted
Jan 16, 2009
Start
Dec 2008
Primary completionActual
Oct 2009
CompletionActual
Mar 2010
Results delay requested
Jul 23, 2012
Results first posted
Apr 1, 2014
Last update
Apr 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00824460
Lead sponsor
Vifor Pharma
Responsible party
Sponsor
First posted
Jan 16, 2009
Start date
Dec 2008
Primary completion
Oct 2009
Completion
Mar 2010
Results posted
Apr 1, 2014
Last update
Apr 1, 2014

Study contacts

Prof. Rudolf P Wutrich, MD
principal investigator · Unafilliated

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iron · Sevelamer

Start the discussion